Skip to content

Whole Exome Sequencing in Coronary Artery Ectasia

Genetic Background Assessment With Whole Exome Sequencing in a Giant Coronary Artery Ectasia: a Pilot Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06001957
Enrollment
1
Registered
2023-08-21
Start date
2022-03-23
Completion date
2023-08-15
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Aneurysm, Coronary Ectasia

Keywords

Coronary ectasia, Coronary aneurysm, Whole exome sequencing, Mutations

Brief summary

The goal of this observational study is to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background. The main question it aims to answer are: * the assessment of role of WES in CAE * the detection of novel pathogenic mutations associated with CAE development

Detailed description

Coronary artery aneurysm and ectasia (CAAE) is defined as a dilation of the coronary artery by at least 1.5 times compared to the adjacent segment. The incidence of CAAE is reported in 0.3-5.3% of patients undergoing coronary angiography. Giant CAAE is a rare phenomenon characterized by a dilation of a coronary artery exceeding 2 to 4 centimeters and it was found only in 0.02% of patients undergoing coronary angiography. The most common etiology of CAAE is atherosclerosis, followed by Kawasaki disease, infectious septic emboli, connective tissue disease and arteritis. Iatrogenic causes are less common. There are few genetic reports on potential loci associated with CAAE. Meta-analysis of genome wide association studies performed in European and Japanese population of children with Kawasaki disease has identified ITPKC, FCGR2A, CASP3 and FAM167A genomic regions to be associated with susceptibility to develop CAAE. Furthermore, 9p21 variant has been linked with coexistence of coronary artery disease, cerebral artery aneurysms and aortic aneurysms, mainly due to suspected potential adverse vascular remodeling. Nevertheless, the direct association of specific genetic variants with CAAE formation, especially with those giants, has not been proven. Therefore, the investigators aim to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background.

Interventions

DIAGNOSTIC_TESTWhole exome sequencing

Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described. Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer.

Sponsors

Medical University of Warsaw
CollaboratorOTHER
Poznan University of Medical Sciences
CollaboratorOTHER
Jagiellonian University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosed giant coronary artery aneurysm and ectasia (CAAE) * high risk of genetic background

Exclusion criteria

* the lack of informed consent for whole exome sequencing (WES) analysis

Design outcomes

Primary

MeasureTime frameDescription
The novel pathogenic mutations associated with CAE developmentUntil June 11, 2023Reads of WES will be aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026